Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“Examining lymphopenia at a high level as it relates to the general population at large gave me great concern. Since the approval of Anktiva, I have delved deeper into the biology of aging and have become and more and more concerned that lymphopenia is a hidden sentinel of mortality and disease for the US general population regardless of disease status.
Since it is now potentially treatable with an IL-15 superagonist, I explored through multiple AI platforms the question of the implications of lymphopenia in the general US population. Below is the unedited AI response I wanted to share. Congress has established a committee on aging and the realization that a fundamental issue facing the American population of chronic disease and mortality with age is lymphopenia, warrants a hearing by congress on this issue.
The question that was asked to Perplexity was: “Give a detailed review of lymphopenia in the general population as it relates to health and survival, how does it relate to oncology incidence and survival.” This is the unedited response from the A.I. Perplexity. Low lymphocyte counts independently predict death from nearly every major cause, yet clinician rarely act on them.
Two landmark population studies, encompassing over 139,000 individuals from Copenhagen and the United States, have established that lymphopenia carries a 1.6 to 1.8-fold increased hazard of all-cause mortality after adjusting for traditional risk factors.
This association extends across cardiovascular disease, cancer, infection, and respiratory illness, with 10-year mortality ranging from 3.8% in immunologically healthy individuals to 62.1% in those with combined lymphopenia, elevated C-reactive protein, and high red cell distribution width.
Lymphopenia affects roughly 2-4% of the general population at the commonly used threshold of <1,000/µL, rising to 20% at the more liberal <1,500/µL cutoff – meaning millions of people carry this underrecognized risk marker on routine blood work that is already being drawn but seldom scrutinized. This review synthesizes evidence from major cohort studies, meta-analyses, and recent trials (2018–2025) to characterize lymphopenia’s epidemiology, prognostic significance, mechanistic underpinnings, and therapeutic frontiers.
One in five Americans may carry an immunohematologic risk they don’t knowabout
The absolute lymphocyte count (ALC) in healthy adults typically ranges from 1,000-4,800 cells/µL, with a population median of approximately 2,000/µL across NHANES and UK Biobank data. No international consensus defines a single lymphopenia threshold.
The most commonly used clinical cutoff is <1,000/µL, though many studies employ <1,500/µL for “relative” lymphopenia, and the Copenhagen General Population Study uses <1,100/µL (the population’s 2.5th percentile). The CTCAE v5.0 oncology grading system stratifies severity further: Grade 1 (800–999/µL), Grade 2 (500–799/µL), Grade 3 (200–499/µL), and Grade 4 (<200/ µL).
Prevalence varies sharply by threshold and population. In NHANES data (n = 31,178 US adults), Zidar et al. (2019,JAMA Network Open) found 20.1% had ALC ≤1,500/µL and 3.0% had ALC ≤1,000/µL. The Copenhagen cohort (n = 98,344) documented 2.4% below 1,100/µL.
A separate NHANES analysis (Xie et al., 2024, PLOS ONE, n = 33,365) revealed prevalence at <1,000/µL stratified by race: White 1.81%, Black 1.08%, and Mexican-American 0.42%. Notably, racial differences in lymphocyte counts are modest – unlike neutrophils, where benign ethnic neutropenia driven by the Duffy-null phenotype affects 60–65% of African Americans. The UK Biobank (n ≈ 477,000) reports a median ALC of 1,880/µL with a 10th percentile of 1,250/µL. Age is the strongest demographic determinant.
Lymphopenia prevalence climbs from under 1% in young adults to 6.84% in those aged ≥75 years (NHANES 2009–2018). Men have significantly higher prevalence than women (P < 0.001), likely reflecting hormonal influences on CD4+ T-cell and B-cell counts.
PLOS In hospitalized populations, lymphopenia prevalence surges to approximately 38% PubMed Central (pooled estimate from a 2023 BMC Infectious Diseases meta-analysis of 15 studies), PubMed underscoring its association with acute and chronic illness.
Population studies link lymphopenia to death from cardiovascular disease, cancer, and infection
The two foundational population-based studies that established lymphopenia as a mortality predictor deserve detailed examination .The Copenhagen General Population Study (Warny et al., 2020, CMAJ) enrolled 108,135 white Danish adults followed for a median of 9 years, during which 10,372 died. After multivariable adjustment for 16 covariates – including smoking, alcohol, BMI, CRP, neutrophil count, diabetes, blood pressure, cholesterol, education, income, and physical activity – lymphopenia was associated with all-cause mortality at HR 1.63 (95% CI 1.51–1.76). Cause-specific hazard ratios were striking:
- cardiovascular disease HR 1.88 (1.61–2.20), respiratory disease HR 1.88 (1.55–2.29)
- infectious disease HR 1.86 (1.53–2.25),
- non-hematologic cancer HR 1.67 (1.42–1.97), and
- hematologic cancer HR 2.79 (1.82–4.28).
Risk was more pronounced in participants ≤70 years (P for interaction < 0.001). PubMed Central The absolute 2-year mortality risk reached 75% in men CMAJ aged ≥80 who smoked and had ALC <0.5 × 10⁹/L. The NHANES cohort analysis (Zidar et al., 2019, JAMA Network Open) studied 31,178 US adults over 12 years.
Age- and sex-adjusted hazard ratios were 1.3 (1.2–1.4) for ALC ≤1,500/µL and 1.8 (1.6–2.1) for ALC ≤1,000/µL. The unadjusted hazard ratios were even more dramatic: severe lymphopenia carried HRs of 4.0 (3.2–5.0) for cardiovascular death, 3.0 (2.3–3.9) for cancer death, and 7.0 (3.4–14.7) for influenza/pneumonia death – while showing no significant association with unintentional injury death (HR 1.3, 0.6–2.7), supporting a biological rather than confounding mechanism.
Critically, Zidar’s group introduced an “immunohematologic risk score” combining lymphopenia, CRP, and RDW: approximately 20% of the US population fell into high-risk categories, with 10-year mortality of 28% versus 4% in low-risk individuals. Cardiovascular disease shows a particularly strong and consistent association. Beyond the population studies, Zafrir etal. (2022) analyzed 15,179 coronary angiography patients (median follow-up 8 years) and found severe lymphopenia(<1,000/µL) independently predicted mortality at HR 1.97 (1.75–2.22).
In heart failure, low lymphocyte count has been prognostic since Ommen et al.’s landmark 1998 Circulation study, with recent data showing HR 1.72 (1.18–2.52) for ALC ≤1,000 in propensity-matched HF cohorts. A 2018 meta-analysis of 38 studies (n = 76,002) confirmed elevated neutrophil-to-lymphocyte ratio (NLR) associated with coronary artery disease (OR 1.62), acute coronary syndromes (OR 1.64), and stroke (OR 2.36).
Infection risk was quantified in the earlier Copenhagen analysis (Warny et al., 2018, PLOS Medicine, n = 98,344): lymphopenia predicted any hospitalized infection at HR 1.41 (1.28–1.56), with specific risks for pneumonia (HR 1.31), skin infections (HR 1.44), urinary tract infections (HR 1.26), and sepsis (HR 1.51).
COVID-19 dramatically highlighted this vulnerability – in 4,485 hospitalized Danish COVID patients, 57.3% had lymphopenia at admission, which predicted ICU admission (OR 1.86), mechanical ventilation (OR 2.09), and in-hospital death (OR 2.19, 1.76–2.72).
Pre-existing lymphopenia predicts cancer, and cancer-associated lymphopenia predicts death
The relationship between lymphopenia and malignancy operates bidirectionally: low lymphocyte counts in the general population predict future cancer mortality, and lymphopenia at cancer diagnosis predicts poor outcomes across virtually all tumor types. Cancer incidence and population risk.
The Copenhagen study found lymphopenia associated with non-hematologic cancer mortality at HR 1.67 and hematologic cancer mortality at HR 2.79. A study of 511 smokers followed for 5 years found those with ALC < 1,800/µL had significantly higher cancer incidence (31% vs. 18%, P = 0.001), with the effect particularly pronounced in smokers without COPD (all cancers 31% vs. 12%, P = 0.003; lung cancer 10% vs. 0%, P = 0.001).
The mechanism is fundamentally one of impaired immune surveillance: fewer cytotoxic T cells and NK cells to eradicate nascent malignant cells, compounded by restricted T-cell receptor repertoire diversity from homeostatic proliferation. Pre-treatment lymphopenia across solid tumors was comprehensively meta-analyzed by Huang et al.
(2020, Cancer Cell International): 42 studies, 13,272 patients with various solid tumors showed low pre-treatment ALC associated with worse overall survival (HR 1.27, 1.16–1.39, P < 0.001) and progression-free survival (HR1.27, 1.15–1.40, P < 0.001).
The landmark study by Ray-Coquard et al. (2009, Cancer Research) demonstrated a remarkably consistent lymphopenia prevalence of 24-27% across metastatic breast cancer, advanced soft-tissue sarcoma, and DLBCL, with lymphopenia independently prognostic in multivariate analysis for all three.
The neutrophil-to-lymphocyte ratio has emerged as the most widely studied composite inflammatory-immune biomarker in oncology. Templeton et al.’s landmark 2014 JNCI meta-analysis (100 studies, 40,559 patients) established that NLR above the median cut off of 4 predicted worse OS across all solid tumors (HR 1.81, 1.67–1.97, P < 0.001).
The effect was strongest in mesothelioma (HR 2.35), pancreatic cancer (HR 2.27), and renal cell carcinoma (HR 2.22). An umbrella review (Howard et al., 2020, BMC Medicine) evaluating 204 meta-analyses confirmed 18 associations supported by strong evidence across multiple tumor types. In hematologic malignancies, lymphopenia is integrated into formal prognostic systems.
The International Prognostic Score for advanced Hodgkin lymphoma (Hasenclever and Diehl, 1998, NEJM; n = 5,141) includes ALC< 600/µL as one of seven adverse factors. In peripheral T-cell lymphoma, lymphopenia frequency reaches 35-47% depending on subtype, with 2-year OS of 15% versus 40% in adult T-cell leukemia/lymphoma (P < 0.001). The lymphocyte-to-monocyte ratio meta-analysis (Gu et al., 2016) confirmed low LMR predicts poor OS in both solid tumors (HR 0.59,0.53–0.66) and hematologic malignancies (HR 0.44, 0.34–0.56).
Treatment-related lymphopenia undermines both conventional and immunologic cancer therapy
Lymphocytes are exquisitely radiosensitive – with a lethal dose (LD50) of only 1–1.5 Gy compared to >50 Gy for most solid tumors – making radiation-induced lymphopenia (RIL) nearly universal during radiotherapy. By the end of treatment, median ALC declines to 24% of baseline (range 1.5–78%), Science Direct with recovery reaching only 55% of baseline within one year Science Direct across 142 published ALC curves.
Two major meta-analyses quantify the survival impact: Damen et al. (2021, IJROBP; 20 studies) reported Grade ≥3 RIL carried a pooled aHR of 1.65 (1.36–2.00) for OS, while El Houat et al. (2023; 56studies, 13,223 patients) found RIL prevalence of 37.25% and an OS hazard ratio of 1.70 (1.55–1.86). The impact varies by anatomic site.
Head and neck cancer shows the highest pooled OS hazard ratio at 2.94 (1.83–4.74) with G3–4 RIL incidence of 73–88%. Cervical cancer demonstrates severe lymphopenia in up to 95% of patients during chemoradiation, with OS HR of 2.67 (1.81–3.94).
Glioblastoma was the subject of the seminal Grossman et al. study (2011, Clinical Cancer Research): 75% of patients developed ALC < 1,000 after RT/temozolomide, with 40% reaching CD4 <200 – a level associated with median OS of 13.1 versus 19.7 months (P = 0.002) and adjusted HR of 1.66 (P = 0.03).
Critically, 88% of deaths were from tumor progression, not infection, directly implicating immune surveillance failure. PubMed In pancreatic cancer, the pooled survival impact was even larger: HR 2.33 (1.79–3.03), Red journal with a mean OS difference of -6.80 months. Chemotherapy-induced lymphopenia compounds the problem.
Grade 3-4 lymphopenia occurs in up to 69% of patients receiving dose-dense anthracycline-cyclophosphamide/taxane regimens. Nature Temozolomide causes selective CD4+ depletion PubMed Central that may persist for over 12 months. Concurrent chemoradiation deepens lymphopenia significantly compared to sequential approaches.
Lymphopenia’s impact on immunotherapy represents perhaps the most clinically consequential finding. Check point inhibitors require functional T cells to “release the brakes” on-fewer T cells means fewer effectors to reactivate. In 179 patients treated with immune checkpoint inhibitors, Teng et al.
(2024, BJC Reports) found lymphopenia at 3 months predicted dramatically shorter OS (9.8 vs. 18.3 months, P < 0.001), while – encouragingly – patients who recovered from baseline lymphopenia by 3 months had outcomes equivalent to never-lymphopenic patients (OS 22 vs. 18.3 months, P = 0.548). In the PACIFIC-relevant setting, Jing et al.
(2022, JTO Clinical Research Reports) showed severe RIL attenuated the survival benefit of durvalumab consolidation in stage III NSCLC, essentially eliminating the immunotherapy advantage in the most lymphopenic patients. The strongest risk factor for on-treatment lymphopenia was prior radiation therapy. A critical paradox exists in CAR-T cell therapy, where intentional pre-infusion lymphodepletion with cyclophosphamide/fludarabine is essential – achieving 50% CR and 72% ORR versus 8% CR with cyclophosphamide alone.
Lymphodepletion reduces regulatory T-cells, increases homeostatic cytokines (IL-7, IL-15), and creates immunologic “space” for CAR-T expansion. This stands in mechanistic contrast to checkpoint inhibitors, which depend on the endogenous lymphocyte repertoire.
Thymic involution, inflammation, and stress converge in a vicious cycle of immune erosion
Lymphopenia’s power as a mortality predictor reflects its position as an integrative biomarker of multiple converging pathological processes. Thymic involution is the central driver of age-related lymphocyte decline. Frontiers The thymus progressively replaces functional epithelium with adipose tissue, reducing naïve T-cell output by approximately 95% between ages 20 and 60.
Compensatory homeostatic proliferation of existing memory T cells maintains total counts but narrows TCR repertoire diversity and expands senescent, poorly functional clones. Young adults who underwent childhood thymectomy for cardiac surgery display premature immunosenescence decades later, providing direct human evidence that thymic function is non-redundant. Chronic inflammation (inflammaging) operates in a bidirectional cycle with lymphopenia.
Immunosenescent lymphocytes fail to clear senescent somatic cells, which accumulate and secrete pro-inflammatory mediators (the senescence-associated secretory phenotype, or SASP), driving further immune dysregulation.
The NHANES immunohematologic risk score elegantly captures this: CRP (inflammation) combined with lymphopenia (immune depletion) and RDW (bone marrow stress) creates a composite that predicts mortality far better than any single marker. Cortisol and chronic stress directly suppress lymphopoiesis. Glucocorticoids induce apoptosis of pre-B cells Pub Med Central and inhibit T-cell proliferation.
This pathway converges with AHA Journals nutritional deficiency – zinc deficiency (affecting ~2 billion people globally) activates the HPA axis, causing chronic glucocorticoid production that accelerates pre-lymphocyte apoptosis while preserving myelopoiesis. A moderate zinc-deficient period in animal models causes a 50% reduction in leukocytes and 40–70% decline in adaptive immune responses.
Vitamin D deficiency correlates with reduced CD8+ T cells and elevated NLR, though direct causal evidence for supplementation-driven lymphocyte recovery remains limited. Malnutrition is the most common cause of lymphopenia worldwide. Chronic viral infections reshape the lymphocyte compartment. CMV-specific T cells can constitute up to 50% of circulating CD8+ T cells, effectively monopolizing immune resources and accelerating repertoire restriction.
HIV directly depletes CD4+ T cells. Both CMV and EBV produce viral IL-10 homologs that broadly suppress immune function. Aging hematopoietic stem cells compound these pressures through myeloid-biased differentiation at the expense of lymphoid lineages.
Conclusion
Lymphopenia emerges from this evidence as one of the most potent – and most neglected – readily available biomarkers in medicine. The convergence of two independent population studies from different continents, each exceeding 30,000 participants, establishes a dose-dependent mortality signal that persists after extensive adjustment and spans every major cause of death.
The finding that roughly one in five Americans carries an adverse immuno-hematologic profile detectable from routine blood work, yet virtually none receive targeted clinical attention for it, represents a substantial gap between evidence and practice. Three insights reshape how we should think about lymphopenia. First, it functions not as a marker of a single disease but as an integrative readout of immune fitness – reflecting the cumulative burden of aging, inflammation, nutritional status, stress, and chronic infection.
Second, in oncology, lymphopenia operates on both sides of the therapeutic equation: it predicts cancer development, worsens prognosis at diagnosis, and – most consequentially for modern practice – attenuates the benefit of immunotherapy, potentially undermining the checkpoint inhibitor revolution for the patients who need it most. Third, the finding that lymphocyte recovery normalizes immunotherapy outcomes suggests a therapeutic window: restoring lymphocyte counts before initiating immune-based therapies could meaningfully improve efficacy.
The path forward requires prospective interventional trials to determine whether correcting lymphopenia – through IL-7, thymic rejuvenation, proton therapy, nutritional optimization, or combinations thereof – actually reduces mortality, rather than merely modifying a biomarker.
Until such evidence exists, a pragmatic minimum would be to flag incidental lymphopenia on routine blood work, investigate reversible causes (medications, nutritional deficiency, viral infections, autoimmune conditions), and ensure high-risk lymphopenic individuals receive appropriate preventive care including cancer screening, vaccination, and cardiovascular risk modification.
The data needed to act on this is already sitting in millions of unread CBC reports.”
Other articles featuring Pat Soon-Shiong on OncoDaily.